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Summary This paper describes a program to increase patients’ treatment literacy regard-
ing viral load (VL) monitoring through patient education materials and a counseling protocol,
implemented by peer counselors, in order to reinforce adherence to ﬁrst-line treatment. VL
monitoring and second-line antiretroviral treatment were introduced into an established ﬁrst-
line treatment program in a rural district hospital in Thailand. All patients (171 adults and 14
children) taking antiretroviral treatment for more than 6 months participated and those with
detectable VL were targeted for additional adherence support. The main outcome measure
recorded was the number of detectable results becoming undetectable after counseling. Four
adults and one child had a persistently high VL and switched to second-line treatment. Of 51
adults (30%) with an initial low detectable VL, 47/51 identiﬁed likely explanations, usually linked
with poor adherence. Following counseling, VL became undetectable in 45/51 cases and somePlease cite this article in press as: Wilson D, et al. HIV-1 vira
adherence in a resource-limited setting in Thailand. Trans R So
patients could resolve long-standing psychosocial problems. We conclude that HIV-1 VL monitor-
ing together with targeted counseling for patients with detectable VL can promote adherence
to treatment, providing an opportunity to delay onset of HIV-1 resistance. When implemented
with a patient-centered approach, it can be a very useful tool for psychosocial support.
© 2008 Royal Society of Tropica
reserved.
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. Introduction
s highly active antiretroviral treatment (HAART) becomes
ncreasingly available in resource-limited settings,1 the
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
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mergence of HIV-1 resistance is becoming a signiﬁcant
hallenge.2,3 Ensuring treatment adherence is essential, and
IV-1 viral load (VL) testing has been recommended to high-
ight poor adherence.4
WHO guidelines recommend VL monitoring primarily to
uide decisions to switch regimens.5 Its additional use to
einforce adherence has been documented in South Africa6,7
nd other resource-limited settings.8 If VL is to be used opti-
ally to reinforce adherence, however, some issues need to
e resolved regarding patients’ understanding and involve-
ent. How should they be prepared to take the test? How
o they interpret the results? To our knowledge there has
een no literature discussing these aspects.
In this article we describe our experience in introducing
L monitoring in a resource-limited setting in Thailand, and
he tools we developed, focusing on treatment literacy and
atient involvement.
. Project description
.1. Setting
uchinarai (population 103 000) is a typical rural district in
ortheastern Thailand. The population are mostly subsis-
ence rice farm laborers. Antenatal HIV prevalence in 2006
as 2.6%, compared with a national rate of 1.0%. First-linePlease cite this article in press as: Wilson D, et al. HIV-1 vira
adherence in a resource-limited setting in Thailand. Trans R So
AART has been available since February 2002. Adherence
s monitored by pill count and self-report, methods that
end to overestimate adherence.9 In August 2006, follow-
ng new Ministry of Public Health guidelines, VL testing and
econd-line HAART were introduced.
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Figure 1 ‘Trafﬁc lights’ poster used to guide patients through PRESS
D. Wilson et al.
.2. HIV-1 VL monitoring
e offered VL counseling and testing to adults and children
aking HAART for a minimum of 6 months (see below).
IV-1 RNA assays were performed in the reference labo-
atory of the Thai Red Cross HIV Clinical Research Centre
sing a b-DNA method with a lower limit of detection of
50 copies/ml. If VL was >1000 copies/ml, genotype
esistance testing was performed.
We divided patients into three categories depending
n the result. Those with undetectable VL proceeded to
monthly monitoring thereafter. Those with low detectable
L (>50 to <1000 copies/ml) were offered additional adher-
nce support and follow-up VL after 3 months: intuitively
reasonable time for solving adherence problems. Patients
ith a high detectable VL (>1000 copies/ml) and conﬁrmed
IV-1 resistance were offered appropriate counseling
ogether with second-line treatment. If genotype testing
ailed to show resistant mutations, they continued ﬁrst-line
reatment and had follow-up VL at 3 months. We recorded
esults of routine clinical follow-up in standardized software
FUCHIA).10
.3. Developing education materials and a pre-
nd post-VL testing protocoll load monitoring: an opportunity to reinforce treatment
c Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.11.007
ur strategy was to use VL testing as an opportunity to help
atients reﬂect on their commitment to treatment, their
dherence and other behavior that possibly leads to resis-
ance, and to make their own decisions on how to change.
e developed educational materials and a counseling pro-
the process of HIV-1 viral load testing. ARV: antiretrovirals.
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Viral load treatment adherence
tocol to guide patients through this process and help them
to link their VL result with their adherence to treatment.
Despite the low educational level of many patients,
explaining the concept of resistance was straightforward
(they were mostly farmers and so familiar with the concept
from pesticide use). The challenges were to develop an edu-
cation tool that explained the three possible results of VL
testing [undetectable (<50 copies/ml), low detectable (>50
copies/ml to <1000 copies/ml) and high detectable (>1000
copies/ml)] in a non-judgmental way, and to overcome the
stigmatizing label ‘treatment failure’.
We tried using three faces (smiling, neutral and frown-
ing) as a visual aid, but the frown raised some extreme
negative feelings. We then tried ‘trafﬁc lights’: every-
day, non-threatening objects indicating three alternative
courses of action, but where certain rules must be observed.
Figure 1 shows a poster developed to guide the process of
self-reﬂection and explain procedures for follow-up test-
ing and future treatment options. This was understood
both by adults and children, the youngest of whom wasPlease cite this article in press as: Wilson D, et al. HIV-1 vira
adherence in a resource-limited setting in Thailand. Trans R So
aged 6.
Once patients understood the purpose and implications of
VL testing, they were encouraged to proceed to pre-VL test
counseling. Table 1 shows our protocol for pre- and post-
counseling. Peer counselors, already experienced in other
V
a
t
w
Table 1 Guideline for pre- and post-VL test counseling.
General points for counselors
• These points apply to counseling for both adults and children.
• The objectives are to change behavior that may lead to the deve
Help patients link their behavior to the VL result, and promote c
patients to decide what aspects of their behavior to change base
• Take a non-judgmental attitude. Avoid the expression ‘treatmen
• Encourage patients to reﬂect on their commitment to treatment
forgot your medicine?’ are better than ‘Why?’ questions, which
medicine?’).
• Counseling should be performed within the context of existing so
one-on-one, or in the presence of friends or family, or during a g
Pre-viral load test counseling
• Give enough basic information to explain the implications of the
each case.
• Ask the patient if he/she wants to proceed with VL testing (he/s
• In case he/she decides to proceed, ask what result he/she expec
he/she will feel, and how he/she will make necessary adjustmen
• Give time for the patient to think through any psychosocial or ot
an appointment for further counselling as appropriate.
Post- viral load test counseling
• Ask what the patient remembers about VL and what he/she expe
• Give the VL result clearly and ensure it is understood.
• Ask again the reasons for the result. Allow time for reﬂection. An
patient’s self-esteem.
• In case of detectable VL, patients may need to release emotions
change behaviour.
• Encourage realistic plans to improve adherence. For example tho
drinking session can be advised to take their medication an hour
be told not to get drunk.
Make a further appointment if necessary.
VL: viral load. PRESS
3
spects of treatment support, quickly developed expertise
o implement this protocol under supervision of a nurse
ounselor.
. Results
e report results for all patients having their ﬁrst VL test
etween August 2006 and December 2007, together with
ollow-up tests until June 2008: 171 adults and 14 children
aged 6 to 12) were eligible; all were tested on at least
hree occasions, and remained in clinical follow-up through-
ut this period (Table 2). At the time of their ﬁrst VL test,
edian time on HAART for adults was 35 months (range 6—62
onths) and for children 47 months (range 17—56 months).
Considerations of previous toxicity, pregnancy or con-
omitant tuberculosis (TB) treatment meant that patients
ere taking a variety of HAART regimens. Most were taking
ither a ﬁxed-dose combination of d4T/3TC/NVP (n = 78) or
4T + 3TC + EFV (n = 43). No association was found betweenl load monitoring: an opportunity to reinforce treatment
c Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.11.007
L and drug regimen (data not shown).
Initial and all follow-up VL were undetectable in 116
dults and 13 children. High VL together with HIV-1 resis-
ance was found in four adults and one 12-year-old child,
ho all switched to second-line regimens.
lopment of HIV-1 resistance and to support the patient.
onﬁdence and skills for behavior change. Encourage
d on their options and own strengths and experiences.
t failure’.
. ‘How?’ questions, such as ‘How did you feel when you
can sound like accusations (‘Why did you forget your
cial network support and may be performed
roup meeting for People with HIV/AIDS.
three possible outcomes and options for treatment in
he has the right to delay or refuse).
ts, based on adherence or other factors. Ask how
ts in case of detectable VL.
her issues that may emerge. Arrange the test or make
cted the result to be.
swer any questions honestly. Always aim to improve the
, before they can consider their different options and
se who forget medication during or after a heavy
or so early, before going out to get drunk, rather than
ARTICLE IN PRESS+ModelTRSTMH-1069; No. of Pages 6
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Table 2 Summary of HIV-1 viral load test results.
n (%)
Adults 171 (100)
VL consistently undetectable (<50 copies/ml) 116 (68)
VL high (>1000 copies/ml) on initial test and HIV-1 resistance detected; switched to second-line regimen 4 (2)
VL low detectable (>50 copies/ml) on one or more occasion a 51 (30)
First VL low detectable a 40 (23)
Follow-up VL after 3 months undetectable (<50 copies/ml) 36 (21)
Follow-up VL after 3 months low detectable (>50 to <1000 copies/ml) but subsequent VL after 6 months or
more undetectable (<50 copies/ml)
1 (0.5)
Further follow-up VL after another 3 months remains low detectable (>50 to <1000 copies/ml) 3 (1.5)
First VL undetectable (<50 copies/ml) and 6 months later second VL low detectable (>50 to <1000 copies/ml) 9 (5)
Further follow up VL after another 3 months undetectable (<50 copies/ml) 8 (4)
Further follow up VL after another 3 months remains low detectable (>50 to <1000 copies/ml) 1 (1)
First and second VL undetectable (<50 copies/ml); third VL low detectable (>50 to <1000 copies/ml) 2 (1)
Further follow-up VL undetectable (<50 copies/ml) 1 (0.5)
Further follow-up VL remains low detectable (>50 to <1000 copies/ml) 1 (0.5)
Children 14
VL consistently undetectable (<50 copies/ml) 13
VL high (>1000 copies/ml) on initial test and HIV-1 resistance detected; switched to second-line regimen 1
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aVL: viral load.
a Among the 51 adults whose ﬁrst VL was low detectable, 49 were
to <2000 copies/ml but no HIV-1 resistance was detected.
Among the remaining adults (51/171), 40 (23%) had
ow detectable VL on their ﬁrst test and 11 (6%) had
ndetectable VL initially but developed low detectable
L later: 9 (5%) on their second test and 2 (1%) on
heir third test. All patients with detectable VL received
month and 6 month follow-up tests. In 47/51 cases, the
esult became undetectable following the intervention. No
atients progressed to high VL with resistance.
.1. Patients’ explanations of detectable VL
he following explanations emerged during counseling ses-
ions. Of 51 adults with low detectable VL, 39 (18 men, 21
omen) linked their result with poor adherence: insufﬁcient
ime to organize taking their medicines (8 men, 3 women);
etting drunk with friends (9 men, 1 woman); fear of disclo-
ure (3 men, 5 women); and stopping or stopping/starting
reatment (2 men, 2 women).
A further eight (6 men, 2 women) had always adhered
ell and identiﬁed regular unsafe sex as the explanation.
our men were very surprised by their detectable VL, or did
ot believe it, and could not put forward any explanation.
The counseling process uncovered unresolved psychoso-
ial issues for some patients (see below). Some patients
ound they had the strength to address these issues. How-
ver, VL testing created negative feelings for some patients,
mphasizing the need for careful assessment during pre-VL
est counseling.Please cite this article in press as: Wilson D, et al. HIV-1 vira
adherence in a resource-limited setting in Thailand. Trans R So
.2. Case histories
.2.1. Toey and Lek
oey and her husband Lek have been married for 10 years.
ek does not like to use condoms during sex; Toey com-
3
L
c
h
He range >50 to <1000 copies/ml, and two were in the range >1000
lained about this from time to time, but the couple had
ever worked through this issue. Since they started HAART,
oey’s adherence has always been good, but Lek occasion-
lly missed some doses. They had their ﬁrst VL tests in
ugust 2006 after 3 years on HAART. Both had detectable
L: Toey 69 copies/ml and Lek 922 copies/ml. Toey became
ore assertive with Lek about her worry that unprotected
ex was increasing their HIV levels. After trying different
inds of safer sex, the couple found coitus interruptus
he most suitable for them. Three months later, Toey’s
L was undetectable although Lek’s remained detectable
59 copies/ml). After 6 months Lek’s VL became unde-
ectable. The couple are more relaxed with each other now
nd feel that talking openly with each other about safer sex
as improved their relationship in general.
.2.2. Ott
tt started HAART in September 2003. In early 2006, his
ife left him, taking their daughter with her. He began to
rink heavily and stopped taking his treatment correctly. He
ttempted to hang himself but was found by his family. Peer
ounselors visited him and told how they had learned to cope
n similar situations. No longer feeling alone, Ott realised he
anted to live and decided to take better care of himself.
e expected to have a very high VL, but the result, although
etectable, was low (172 copies/ml) and motivated him fur-
her to adhere to treatment. Three months later his VL was
ndetectable. He now feels he can put the past behind him
nd look to the future.l load monitoring: an opportunity to reinforce treatment
c Trop Med Hyg (2008), doi:10.1016/j.trstmh.2008.11.007
.2.3. Leu
eu, his wife and his son are all HIV-positive. Leu developed
ryptococcal meningitis in 2003, and felt desperate until
e heard about HAART. All three family members started
AART, were highly motivated, and had good adherence. In
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October 2006 they had VL testing; Leu’s VL was detectable
(298 copies/ml), although his wife’s and son’s were unde-
tectable. Old feelings of despair returned when he heard
this result and he wanted to give up treatment. His peer
counselor persuaded him to continue, and 3 months later a
follow-up VL was undetectable.
4. Discussion
In 45/51 patients, low detectable VL became undetectable
following counseling and behavior change. How should these
data be interpreted? The causation and signiﬁcance of VL in
the range >50 to <1000 copies/ml are debated9 and the con-
cept of ‘blips’ (transient low-level viremia without clinical
consequences) complicates the picture.11,12 Similar numbers
of blips could plausibly be expected to occur at the time of
the ﬁrst, second and third VL, but among our patients 23%
had low detectable VL on their ﬁrst test and only 6% devel-
oped detectable VL later. Opportunistic infections can result
in transient increases in VL,8,13 but at the time of VL testing,
only two patients had ongoing opportunistic infections (CMV
retinitis and extra-pulmonary TB). VL was undetectable, and
remained so, in both these patients, so this is an unlikely
explanation for the trends. The explanations identiﬁed by
patients themselves, mostly linked with poor adherence,
remain a likely cause. More importantly, these proved to
be an entry point for discussion on patients’ commitment to
treatment.
Poor treatment adherence, the commonest cause of
treatment failure, can be improved: in one program in South
Africa, where patients with detectable VL receive targeted
adherence support by peer counselors, only 2% patients
developed persistent virological failure.7 Treatment literacy
is a factor contributing to improved adherence and is associ-
ated with improved outcomes on HAART.14,15 The adherence
support provided by patient groups adds signiﬁcantly to life
years saved in Thailand’s treatment program,16 and the 100%
follow-up rate in our program may be related to the patient-
centered approach taken.
A recent modeling study concluded that VL monitoring
provides only a modest beneﬁt in resource-limited settings
when a single VL is used solely for deciding when to switch
to second-line treatment.17 However, the model did not con-
sider the potential of VL as an adherence reinforcement
tool.18 In Thailand the cost of VL ($US59 per test) and geno-
typing ($US47 per test) is not unaffordable, at least for
program-surveillance purposes. The role of patient educa-
tion and meaningful participation by patients in the process
of VL monitoring also merits wider attention.
In conclusion, VL monitoring and targeted counseling for
patients with detectable results can provide an opportunity
for promoting adherence to ﬁrst-line treatment. VL can be
as much a tool for psychosocial support as a biomedical tool
to detect treatment failure. Educating patients and taking
psychosocial aspects into consideration provides opportuni-
ties to delay the onset of HIV-1 resistance and to supportPlease cite this article in press as: Wilson D, et al. HIV-1 vira
adherence in a resource-limited setting in Thailand. Trans R So
patients.
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